Gold Coast Health Plan℠
A Public Entity

www.goldcoasthealthplan.org

Memorandum

To: Gold Coast Health Plan Providers

From: Lily Yip, Pharm.D., MBA, APh, CDCES, BCACP, CPHQ, Director of Pharmacy

Re: FDA Drug Recall and Voluntary Market Withdrawal

Date: Aug. 28, 2026

This is a notification regarding multiple Food and Drug Administration (FDA) drug recalls / voluntary manufacturer withdrawals that may impact Gold Coast Health Plan (GCHP) members. Please see below for detailed information regarding each affected product.

Recall / Withdrawal #1
Drug: Acamprosate Calcium, delayed-release 333 mg tablets
Manufacturer: Mylan Pharmaceuticals Inc.
Reason for Recall / Withdrawal: Failed dissolution specifications
Effective Date: July 24, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Acamprosate Calcium	Delayed-Release 333mg	Tablets	00378-6333-80	3227809	Oct. 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-800-796-9526 5 a.m. - 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #2
Drug: Levothyroxine Sodium 25 mcg (0.025 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	25 mcg (0.025 mg)	Tablets	16729-0447-17	D2401927	Aug. 31, 2026
				D2401833	Aug. 31, 2026
				D2402551	Nov. 30, 2026
				D2402552	Nov. 30, 2026
				D2500220	Dec. 31, 2026
				D2500223	Jan. 31, 2027

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #3
Drug: Levothyroxine Sodium 50 mcg (0.05 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: August 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	50 mcg (0.05 mg)	Tablets	16729-0448-17	D2401834	Aug. 31, 2026
				D2401982	Aug. 31, 2026
				D2402584	Nov. 30, 2026
				D2402585	Nov. 30, 2026
				D2402586	Nov. 30, 2026
				D2402588	Nov. 30, 2026
				D2402587	Nov. 30, 2026
				D2402589	Nov. 30, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #4
Drug: Levothyroxine Sodium 75 mcg (0.075 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	75 mcg (0.075 mg)	Tablets	16729-0449-17	D2402016	Aug. 31, 2026
				D2402017	Aug. 31, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #5
Drug: Levothyroxine Sodium 88 mcg (0.088 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	88 mcg (0.088 mg)	Tablets	16729-0450-17	D2401813	Aug. 31, 2026
				D2401814	Aug. 31, 2026
				D2500200	Dec. 31, 2026
				D2500219	Dec. 31, 2026

FDA Recall / Withdrawal Notice

Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #6
Drug: Levothyroxine Sodium 100 mcg (0.1 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	100 mcg (0.1 mg)	Tablets	16729-0451-17 16729-0451-15	D2402186 D2402019 D2402094 D2500022 D2500023 D2500021	Sep. 30, 2026 Aug. 31, 2026 Sep. 30, 2026 Dec. 31, 2026 Dec. 31, 2026 Dec. 31, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #7
Drug: Levothyroxine Sodium 112 mcg (0.112 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	112 mcg (0.112 mg)	Tablets	16729-0452-17	D2402443 D2402444 D2402445	Oct. 31, 2026 Oct. 31, 2026 Oct. 31, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. EST (Monday - Friday)

Recall / Withdrawal #8
Drug: Levothyroxine Sodium 125 mcg (0.125 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	125 mcg (0.125 mg)	Tablets	16729-0453-17	D2401983 D2402640 D2402641 D2500224	Aug. 31, 2026 Nov. 30, 2026 Nov. 30, 2026 Jan. 31, 2027

FDA Recall/Withdrawal Notice

Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #9
Drug: Levothyroxine Sodium 137 mcg (0.137 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	137 mcg (0.137 mg)	Tablets	16729-0454-15 16729-0454-17	D2402125 D2402126 D2402127 D2402523 D2402524	Sep. 30, 2026 Sep. 30, 2026 Sep. 30, 2026 Nov. 30, 2026 Nov. 30, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #10
Drug: Levothyroxine Sodium 150 mcg (0.150 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	150 mcg (0.150 mg)	Tablets	16729-0455-17	D2402195 D2402196 D2402197	Sep. 30, 2026 Sep. 30, 2026 Sep. 30, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #11
Drug: Levothyroxine Sodium 175 mcg (0.175 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	175 mcg (0.175 mg)	Tablets	16729-0456-15 16729-0456-17	D2402642 D2401832 D2402525 D2402527 D2402526 D2402643	Nov. 30, 2026 Aug. 31, 2026 Nov. 30, 2026 Nov. 30, 2026 Nov. 30, 2026 Nov. 30, 2026

				D2402644	Nov. 30, 2026

FDA Recall/Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #12
Drug: Levothyroxine Sodium 200 mcg (0.2 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	200 mcg (0.2 mg)	Tablets	16729-0457-15	D2402430	Oct. 31, 2026
			16729-0457-17	D2402431	Oct. 31, 2026
				D2402432	Oct. 31, 2026
				D2500180	Dec. 31, 2026

FDA Recall / Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5 a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #13
Drug: Levothyroxine Sodium 300 mcg (0.3 mg) tablets
Manufacturer: Accord Healthcare, Inc.
Reason for Recall / Withdrawal: Subpotent drug
Effective Date: Aug. 6, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Levothyroxine Sodium	300 mcg (0.3 mg)	Tablets	16729-0458-15	D2402337	Oct. 31, 2026

FDA Recall/Withdrawal Notice
Manufacturer Communication: 1-866-941-7875 5a.m. – 2 p.m. PST (Monday - Friday)

Recall / Withdrawal #14
Drug: Thyroid 30 mg tablets
Manufacturer: Vitruvias Therapeutics Inc
Reason for Recall/Withdrawal: Subpotent drug
Effective Date: Aug. 21, 2026

Product Name	Strength	Dosage Form	NDC	Lot Number(s)	Expiration Date(s)
Thyroid	30 mg	Tablets	69680-0166-00	504950	Sep. 30, 2026

FDA Recall/Withdrawal Notice
Manufacturer Communication: 1- 256-239-9373 6 a.m.- 3 p.m. PST (Monday - Friday) or email safety@vitruvias.com

Clinical Considerations

Providers should:

- Review patient records to identify individuals receiving affected product(s).
- Evaluate patients for potential clinical impacts related to the recall or withdrawal.
- Discontinue use of affected product(s) as appropriate.
- Transition patients to an appropriate alternative therapy when clinically indicated.
- Monitor patients for potential adverse events and/or treatment interruptions.

Member Notification

GCHP has identified and notified potentially affected members by letter regarding this drug recall / withdrawal.

Additional Information

For additional details regarding this drug recall/withdrawal, please refer to:

- FDA Drug Safety Communications
- FDA Recalls, Market Withdrawals, & Safety Alerts
- MedWatch: The FDA Safety Information and Adverse Event Reporting Program
- The FDA Weekly Enforcement Report

For additional questions, please email GCHP Pharmacy Services Department at Pharmacy@goldchp.org.